Research programme: liver cell transplant therapy - Vesta Therapeutics

Drug Profile

Research programme: liver cell transplant therapy - Vesta Therapeutics

Alternative Names: Progenitor liver cell transplant therapy - Vesta Therapeutics

Latest Information Update: 26 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vesta Therapeutics
  • Developer Clinical Data; Vesta Therapeutics
  • Class Cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Liver disorders

Most Recent Events

  • 26 Apr 2012 No development reported - Preclinical for Liver disorders in USA (IV)
  • 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
  • 25 Jan 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top